当前位置：
X-MOL 学术
›
J. Formos. Med. Assoc.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study
Journal of the Formosan Medical Association ( IF 3.2 ) Pub Date : 2024-03-27 , DOI: 10.1016/j.jfma.2024.03.008 Kon-Ping Lin , Chih-Chao Yang , Yi-Chung Lee , Ming-Jen Lee , John Vest , Marianne T. Sweetser , Matthew T. White , Prajakta Badri , Sung-Tsang Hsieh , Chi-Chao Chao
Journal of the Formosan Medical Association ( IF 3.2 ) Pub Date : 2024-03-27 , DOI: 10.1016/j.jfma.2024.03.008 Kon-Ping Lin , Chih-Chao Yang , Yi-Chung Lee , Ming-Jen Lee , John Vest , Marianne T. Sweetser , Matthew T. White , Prajakta Badri , Sung-Tsang Hsieh , Chi-Chao Chao
To examine the efficacy and safety of patisiran, an RNA interference therapeutic, in patients from Taiwan with hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy. The APOLLO phase 3 trial included patients from Taiwan who received patisiran 0.3 mg/kg intravenously or placebo once every 3 weeks (q3w) for 18 months (18 M), followed by patisiran 0.3 mg/kg q3w in an ongoing global open-label extension (OLE) study. The primary endpoint was change from baseline in modified Neuropathy Impairment Score +7 (mNIS+7) at 18 M. Eighteen Taiwanese patients were enrolled in APOLLO (patisiran, n = 8; placebo, n = 10; all A97S gene variant) and 14 continued in the global OLE. In this Taiwanese sub-population, beneficial treatment effects at 18 M were observed in mNIS+7 (least squares mean difference in change from baseline [patisiran-placebo], −26.5 points; 95% confidence interval: −45.5, −7.5). Patients who switched from placebo to patisiran demonstrated slowing of polyneuropathy progression at month 12 in the global OLE, while those who received patisiran in APOLLO maintained the beneficial treatment effects. Patisiran had an acceptable safety profile in the Taiwanese sub-population. This analysis suggests that patisiran is well tolerated and may provide a substantial clinical benefit for Taiwanese patients with hATTR amyloidosis with polyneuropathy. The studies were registered on the . The APOLLO study identifier is NCT01960348 (), with the registration date of October 10, 2013, and the first patient was enrolled on December 13, 2013. For the global OLE, the identifier is NCT02510261 () with the registration date of July 29, 2015, and the first patient was enrolled on July 13, 2015. This study provides Class II evidence that treatment with patisiran is safe and efficacious in Taiwanese patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy.
更新日期：2024-03-27
京公网安备 11010802027423号